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ARTICLE
Long-Term Rescue of a Lethal Inherited Disease by Adeno-
Associated Virus–Mediated Gene Transfer in a Mouse Model
of Molybdenum-Cofactor Deficiency
S. Ku¨gler, R. Hahnewald, M. Garrido, and J. Reiss
Molybdenum cofactor (MoCo) deficiency is a progressive neurological disorder that inevitably leads to early childhood
death because of the lack of any effective therapy. In a mouse model of MoCo deficiency type A, the most frequent form
of this autosomal recessively inherited disease, the affected animals show the biochemical characteristics of sulphite and
xanthine intoxication and do not survive 12 wk after birth. We have constructed a recombinant-expression cassette for
the gene MOCS1, which, via alternative splicing, facilitates the expression of the proteins MOCS1A and MOCS1B, both
of which are necessary for the formation of a first intermediate, cyclic pyranopterin monophosphate (cPMP), within the
biosynthetic pathway leading to active MoCo. A recombinant adeno-associated virus (AAV) vector was used to express
the artificial MOCS1 minigene, in an attempt to cure the lethal MOCS1-deficient phenotype. The vector was used to
transduce Mocs1-deficient mice at both 1 and 4 d after birth or, after a pretreatment with purified cPMP, at 40 d after
birth. We report here that all Mocs1-deficient animals injected with a control AAV–enhanced green fluorescent protein
vector died ∼8 d after birth or after withdrawal of cPMP supplementation, whereas AAV-MOCS1–transduced animals show
significantly increased longevity. A single intrahepatic injection of AAV-MOCS1 resulted in fertile adult animals without
any pathological phenotypes.
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Molybdenum cofactor (MoCo) is essential for the function
of the mammalian enzymes aldehyde oxidase, xanthine
dehydrogenase, and sulphite oxidase.1 The biosynthetic
pathway leading to MoCo requires several enzymes en-
coded by the genes MOCS1, MOCS2, MOCS3, and GEPH.2
Mutations in any of these genes abolish formation of ac-
tive MoCo, leading to the pleiotropic loss of all MoCo-
dependent enzymes and resulting in elevated levels of cy-
totoxic sulphite and xanthine. Elevated sulphite levels
cause progressive neuronal loss and death before adoles-
cence in affected patients. No curative treatment is cur-
rently available. All forms of this disease are inherited au-
tosomal recessively, and most patients harbor mutations
in the gene MOCS1. Loss of MOCS1 function—MoCo de-
ficiency type A (MIM 252150)—results in the inability to
catalyze the first step in MoCo biosynthesis, which leads
to precursor Z. Precursor Z has recently been renamed “cy-
clic pyranopterin monophosphate” (cPMP).1
We described elsewhere the construction of a murine
model for MoCo deficiency type A,3 which has no detect-
able residual Mocs1 mRNA levels. Using this null mutant
animal model, we demonstrated the feasibility of a sub-
stitution therapy with cPMP purified from Escherichia coli
extracts.4 However, this substitution therapy required fre-
quent and lifelong injections of cPMP because of the short
half-life of both the molecule and the MoCo-dependent
enzymes. Furthermore, the production of purified cPMP on
a scale sufficient for the treatment of patients has proven
difficult (G. Schwarz, personal communication).
We therefore set out to explore the possibilities of so-
matic gene therapy for MoCo deficiency. Since the use of
integrating viruses is potentially associated with genotox-
icity,5 we used AAV vectors (the genome of which is main-
tained episomally) to deliver the MOCS1 gene into Mocs1-
deficient mice. This approach required the construction
of an expression cassette suitable for the long-term ex-
pression of both MOCS1A and MOCS1B, as well as for
packaging into a recombinant AAV vector.
We report here that a single injection of an AAV carrying
the MOCS1 expression cassette is sufficient to suppress the
severe MoCo-deficiency phenotype and results in fertile
adult animals. This study, to our knowledge, is the first
reported to use curative gene therapy in a mouse model
of an inherited metabolic disease that has complete mor-
tality in early childhood and, thus, represents an impor-
tant step forward in the therapy for patients with previ-
ously incurable conditions.
Material and Methods
Construction of the MOCS1A/1B Expression Cassette
The enhancer region of the cytomegalovirus (CMV) promoter was
amplified from a template plasmid (pCURE) constructed previ-
ously in our laboratory. The promoter region of the human b-
actin gene was cloned from a BAC (ResGen). The polyadenylation
(polyA) signal of the bovine growth hormone (BGH) gene was
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Figure 1. Structure of the MOCS1 expression cassette. The first
stop codon, terminating the MOCS1A protein, is partially omitted
via alternative splicing, which facilitates expression of the MOCS1B
protein. Both proteins are necessary for the formation of cPMP.
amplified from the plasmid pCURE. Combined with a kanamycin
resistance gene (from pACYC) and an origin of replication (from
pUC9), these elements form the plasmid pCURE2, with a unique
NotI-cloning site between the promotor and polyA signal.
Into this NotI site, the “Reiss variant” of the human MOCS1
cDNA6 was inserted, and, by the use of various restriction sites,
the complete intron 9 of the human MOCS1 gene was first in-
serted between exons 9 and 10 and was subsequently deleted to
a final size of 0.7 kbp, leaving 5′ and 3′ splice sites and the branch-
point region unchanged. The resulting plasmid, pRitaIX, was am-
plified in E. coli cells, which confirmed a functional kanamycin
resistance gene and origin of replication. All other parts of the
final plasmid were completely sequenced to exclude PCR errors,
mutations, or cloning artifacts. The expression cassette has a total
size of 3.6 kbp (fig. 1), and the primary transcript (with a size-
reduced intron 9) has a size of 2.8 kbp.
Establishment of a Transgenic Mouse Strain
The plasmid pRitaIX was linearized by a restriction digest of a
unique site of the kanamycin resistance gene and was injected
into the male pronucleus of fertilized oocytes, which were sub-
sequently reimplanted into a pseudopregnant foster mother. The
resulting offspring were tested for the presence of the recombi-
nant human MOCS1 gene, by PCR analysis of tail-tip DNA, and
three positive founder animals were mated with heterozygous
Mocs1-knockout mice to obtain heterozygous animals (Mocs1/)
with additional copies of the MOCS1 human recombinant trans-
gene (MOCS1rhuman). A small portion of the tail biopsy was used
for RNA isolation, to confirm transcription and alternative splic-
ing by RT-PCR. Heterozygous Mocs1-knockout mice with the ad-
ditional transgene (Mocs1/ and MOCS1rhuman) were mated, to
obtain homozygous mice without a functional endogenous Mocs1
gene with the additional transgene (Mocs1/ and MOCS1rhuman).
AAV Vector Preparation and Applications
Recombinant AAV particles were generated essentially as de-
scribed elsewhere,7,8 with the exception that the AAV-2–based ge-
nome was packaged into an AAV–1/2 chimeric capsid, which has
been demonstrated to have high transduction efficacy for both
liver and muscle.9 A 50:50 ratio of AAV-1 and AAV-2 packaging
plasmids was used for this purpose. Vectors were initially purified
by iodixanol gradient centrifugation and were further purified
and concentrated by fast-protein liquid chromatography on Hep-
arin affinity columns (Amersham). After extensive dialysis against
PBS, vectors were stored at 80C until they were used. Genome
copies were determined by quantitative PCR, and purity of 199%
was confirmed by PAGE. Functional titres (transducing units [tu])
were determined by transduction of cultures of primary neurons
and revealed a ratio of 1:30 (tu:genomes) for the AAV–enhanced
green fluorescent protein (EGFP) vector. Since the AAV-MOCS1
vector was prepared identically, the same tu:genome ratio was
assumed for this construct.
Neonatal mice were injected intrahepatically at 1 d after birth
with 10 ml containing 1#109 tu and, after genotyping, were rein-
jected at age 4 d with 50 ml containing 3#109 tu of either AAV-
EGFP ( ) or AAV-MOCS1 ( ). For vector application intonp 10 np 9
adolescent mice, we first confirmed that both tail vein and direct
intrahepatic injection of 1010 tu AAV-EGFP in a volume of 100 ml
resulted in similar tissue transduction (i.e., gene expression pre-
dominantly in hepatocytes). Nineteen Mocs1-deficient animals
were pretreated for 40 d with purified cPMP from E. coli (i.e.,
intrahepatic injection every other day in amounts increasing
from 2 mg in the 1st wk to 32 mg in the 5th wk and after). At age
40 d, 9 animals received an intrahepatic injection of 100 ml AAV-
MOCS1 (8#109 tu), and 10 animals received the same dosage of
AAV-EGFP.
Tissue Preparations
Tissue for expression analysis was prepared from paraformalde-
hyde-perfused mice, was cryoprotected in sucrose, and was stored
at 80 until analysis. Cryostat sections 50 mm thick were pre-
pared for EGFP expression analysis. Confocal pictures were re-
corded by a Leica SP5 microscope.
Biochemical Analysis
Urinary sulphite levels were determined semiquantitatively with
test strips (Merckoquant sulphite test 1.10013.0001), and total
liver molybdopterin (MPT) content and sulphite oxidase activity
in liver tissue were measured as described elsewhere.4
Results
Construction of the MOCS1 Expression Cassette and
Functional Testing in Transgenic Mice
The MOCS1 expression cassette used in this study is shown
in figure 1 and contains (i) a hybrid promoter consisting
of a CMV enhancer region and a human b-actin core pro-
moter, (ii) elements of the human MOCS1 gene: exons 1b,
1c, and 1d (one of three possible splice forms6); exons 2–
9; a deleted intron 9, which allows for alternative splicing
leading to the gene products MOCS1A and MOCS1B; and
exon 10, and (iii) the polyA signal of the BGH gene.
Since antibodies to monitor proper expression of both
MOCS1A and MOCS1B are not available, functional eval-
uation of this construct was first achieved by a transgenic
approach. The cassette was introduced as a transgene in
a wild-type mouse strain (MOCS1rhuman), which was then
crossed with mice heterozygous for a disrupted endoge-
nous Mocs1 gene (Mocs1/) to obtain animals heterozy-
gous for the murine Mocs1 with an additional copy of the
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Figure 2. Survival and enzymatic activity of Mocs1-deficient mice with or without treatment. Group 1 (a) was injected with AAV-
MOCS1 (AAV-EGFP as control) on postnatal days 1 and 4. Group 2 (b) was pretreated with cPMP as described elsewhere4 until age 40
d and was then injected with recombinant AAV. The untreated offspring (c) are the result of four matings of Mocs1-deficient mice of
group 2 injected with AAV-MOCS1 or of matings of two heterozygous mice as a control. d, Sulphite oxidase (SOX) activity in liver tissue
of heterozygous (/) and wild-type (/) animals, in comparison with that of deficient (/) animals with or without AAV-MOCS1
injections as indicated or carrying an additional recombinant transgene (rTG). One column represents one animal, which was measured
in triplicate. Note that the four animals indicated in panels a and b (two in each) were sacrificed with healthy phenotypes for enzymatic
evaluation.
recombinant transgene (Mocs1/ and MOCS1rhuman). Five
matings of 2 animals with Mocs1/ and MOCS1rhuman re-
sulted in a total of 56 offspring, from which 15 (27%) were
genotyped Mocs1/.
Of these 15 animals, 5 carried no recombinant transgene
(MOCS1rhuman) and died at age 4–12 d. Ten animals carried
the recombinant transgene on a double-knockout back-
ground (Mocs1/ and MOCS1rhuman) and developed with-
out a detectable phenotype. They were visually indistin-
guishable from their littermates with an endogenous
Mocs1 wild-type allele and showed only marginally ele-
vated sulphite levels (∼50 mg/liter) in their urine.
At age 43 d, two animals with Mocs1/ and MOCS1rhuman
were sacrificed, and the subsequent autopsy showed nor-
mal development of all organs. Biochemical analysis of
liver tissue revealed a sulphite oxidase activity of ∼50% of
the wild-type level (fig. 2d). By the time this article was
prepared, the remaining eight mice all showed no symp-
toms of MoCo deficiency and were older than 12 mo. We
interpret these results, together with data published else-
where, to indicate stable expression of a functional
transgene.4
Tissue-Transduction Properties of the Recombinant AAV
Vector
cPMP is a small molecule that can diffuse from cells in
which it is synthesized to neighboring cells, and in which
it activates sulphite oxidase, xanthine dehydrogenase, and
aldehyde oxidase.10 This diffusion allows for organwide
supply of cPMP by delivery of the MOCS1 gene to a limited
number of cells. The liver is the organ mainly involved in
detoxification of sulphite by sulphite oxidase.11 Thus, gene
transfer of the MOCS1 gene is primarily aimed at hepa-
tocyte transduction. To trace expression of the recombi-
nant AAV vector, MOCS1 was replaced by the fluorescent
reporter EGFP. This AAV-EGFP vector was injected intra-
venously or intrahepatically into adolescent mice or in-
trahepatically into newborn mice.
In adult mice, injection of 1#1010 tu AAV-EGFP, either
directly into the liver or intravenously into the tail vein,
resulted in almost complete transduction of hepatocytes
(fig. 3a and 3e). Single injections were sufficient to trans-
duce hepatocytes throughout the adult liver in all three
liver lobes, as assayed 4 wk after injection. Very little trans-
Figure 3. Tissue transduction of AAV-EGFP vector after application in adult and neonatal mice. Wide-field (a–d, h–k, and l–o) and
confocal (e–g and p–u) images were obtained from 50-mm cryosections. Confocals represent “enlargements” of the respective tissue
sections, as recorded by wide-field microscopy. Fluorescence is shown as an overlay of EGFP (green) and nuclear DAPI (blue) fluorescence.
Note that wide-field images were recorded with different exposure (exp.) times for EGFP as indicated. a–g, Transduction of adult mice.
h–u, Transduction of neonatal mice. All tissue was sampled at 1 mo after transduction, with the exception of that shown at 7 d (h)
and at 2 mo (k) after transduction. u, Arrows point to small vessels. Scale bars p 400 mm (a–d, h–k, and l–o) and 75 mm (e–g and
p–u). IH p intrahepatic.
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Figure 4. Phenotype of homozygous Mocs1-deficient mice after
AAV-MOCS1 treatment. a, Unaffected heterozygous mouse at age
8 d (left), in comparison with an age-matched AAV-EGFP–injected
homozygous Mocs1-deficient animal (middle) and a homozygous
Mocs1-deficient littermate injected with AAV-MOCS1 at ages 1 and
4 d (right). b, Same animals (left and right in a) at age 66 d (the
AAV-EGFP–injected animal died at age 9 d).
duction was detected in other organs inspected, such as
the heart, the lungs, and the brain (fig. 3b–3d, 3f, and 3g).
Intravenous and intrahepatic vector application resulted
in essentially the same tissue transduction of the AAV vec-
tor (not shown).
Since proper tail-vein injection is not possible in new-
born mice, only intrahepatic injections with 5#109 tu
AAV-EGFP were performed at age 6 d. Livers analyzed 7 d
after vector application showed complete transduction of
hepatocytes (fig. 3h). The mouse liver increases in weight
∼20-fold between the neonatal and adult states. Because
of the episomal nature of the AAV-vector genome, the
number of transgene-expressing hepatocytes accordingly
decreased considerably over time: ∼5% of hepatocytes still
expressed EGFP 4 wk after transduction of the neonatal
liver (fig. 3j, 3l, and 3p). However, 8 wk after transduction,
no further decrease of transgene-expressing hepatocytes
was detected (fig. 3k).
In contrast to vector applications in adult animals, in-
jections into neonatal livers resulted in expression in sev-
eral tissues. We detected strong EGFP expression in car-
diomyocytes throughout the heart muscle (fig. 3n and 3r)
and widespread expression in lung epithelia (fig. 3m and
3q), although at a considerably lower level than in the
liver and heart (note the different exposure times for the
recording of EGFP fluorescence in fig. 3). Intriguingly,
brain transduction was also observed: inside the ventri-
cles, cells of the choroids plexus showed pronounced
EGFP expression (fig. 3o and 3s), whereas, in the brain
parenchyma, several cells with astrocytic morphology ex-
pressed EGFP (fig. 3t). Small-vessel epithelia and very few
neurons also expressed EGFP (fig. 3u). As judged by EGFP
fluorescence levels, transgene expression remained stable
in the transduced tissues, with no detectable decline from
1 to 2 mo after vector application.
Since the above-described AAV-EGFP applications dem-
onstrated divergent tissue tropism between mice injected
at the neonatal and adult states, we treated two groups of
Mocs1-deficient mice at different ages with the AAV-
MOCS1 vector.
Treatment of Newborn Mice with AAV-MOCS1
Complete litters of newborn offspring from the mating of
heterozygous knockout mice (Mocs1/) were injected into
the liver with 1#109 tu of either AAV-MOCS1 or AAV-EGFP
at age 1 d. After identification of homozygous knockout
mice (Mocs1/) by genotyping, these mice were reinjected
with 4#109 tu of the corresponding virus preparation at
age 4 d. Whereas the AAV-EGFP–injected homozygous
knockout mice ( ) showed the typical pathologicalnp 10
phenotype and died after an average life span of 8.4 d (fig.
2a), only 4 of the 9 AAV-MOCS1–injected homozygous
knockout animals ( ) have died so far (at ages 50 d,np 9
118 d, 124 d, and 137 d). Autopsy of the deceased animals
revealed obstructed kidneys as the most probable cause of
death. Because of the short half-life of restored xanthine
dehydrogenase, the animals develop xanthine stones in
the kidneys and sometimes have renal failure.4
After normal results in the open field test (i.e., loco-
motion, leaning, rearing, and cleaning), two mice were
sacrificed at ages 73 d and 64 d, respectively. As a quan-
tifiable parameter for MoCo biosynthesis, total MPT (fig.
1) content in the liver was measured by the nit1 mutant
reconstitution assay4 and was ∼2% of the wild-type level
(not shown). Sulphite oxidase activity in the liver was∼5%
of the wild-type level (fig. 2d). The only observable organ
malformation was, again, of the kidneys, which showed
signs of obstruction to a variable extent. The remaining
three animals of this series were indistinguishable from
their healthy littermates (fig. 4), showed urinary sulphite
levels comparable to those of the transgenic mice (50 mg/
liter), and, by the time this article was prepared, had
reached an average life span of 154 d (fig. 2a). No off-
spring were obtained from matings between animals of
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this series, which could be explained by either urogenital
xanthine obstruction or impaired maternal sulphite
clearance.12
Treatment of Adolescent Mice with AAV-MOCS1
Mocs1-deficient mice do not survive for 12 wk without
treatment.3 However, regular injections of purified cPMP
allow them to reach adulthood, although they show re-
duced activity between ages 20 d and 40 d. We used Mocs1-
deficient mice treated with isolated cPMP until age 40 d,
as described elsewhere,4 to elucidate the effect of intra-
hepatic AAV-MOCS1 injections ( ) in comparisonnp 9
with AAV-EGFP injections ( ) after withdrawal of thenp 10
biochemical substitution therapy with cPMP.
As shown in figure 2b, the animals mock injected with
AAV-EGFP (1010 tu) died, on average, 11 d after the final
cPMP injection. However, only one animal injected with
AAV-MOCS1 (1010 tu) died 14 d after the AAV injection
(cause of death unknown). Four pairs of the surviving an-
imals were mated, and all four matings were fertile. All
offspring ( ) died at age 1–13 d (average 7.5 d). Sincenp 82
the average life span without treatment is the same,3 this
is indirect evidence that no germline transmission of the
vector genome occurred (fig. 2c).
Mice injected at 40 d after birth revealed no abnor-
malities in the open field test, and two of them were sac-
rificed at 60 and 80 d after AAV-MOCS1 injection. The MPT
content in liver tissue was ∼50% of the wild-type level,
and sulphite oxidase activity was ∼75% (fig. 2d). Autopsy
revealed unobstructed kidneys. At the time this article was
prepared, the six remaining animals had reached an av-
erage age of 151 d (fig. 2b). Urinary sulphite levels are ∼50
mg/liter, similar to those of transgenic mice.
Discussion
To date, human clinical gene-therapy trials for inherited
diseases have not been unequivocally successful. Because
of serious adverse events, such as in the X-SCID (X-linked
severe combined immunodeficiency) trials, some studies
using retroviral vehicles have been halted.5 Whereas the
use of AAV vectors for the treatment of hemophilia has
been successfully demonstrated in mice and nonhuman
primates,13 human subjects present new difficulties due to
the lack of reliable test criteria. Transgene-expression lev-
els were low, and corresponding benefits were difficult to
quantitate, which can be explained by the availability of
a substitution alternative (FactorIX) and consequent com-
pliance deficits.14 Further, memory cells created during
previous AAV infections might be stimulated selectively
and eliminate transduced cells, which present fragments
of the viral capsid on their surfaces.15
These problems may be negligible in the treatment of
MoCo deficiency. Patients with MoCo deficiency are given
diagnoses in the first weeks or months of their lives and
would probably not have been exposed to natural AAV
infections. Thus, preexisting immunity may not interfere
with the gene-transfer approach. We demonstrated here
that the subjects with devastating disease can be rescued
by a single gene-therapy treatment. Expression levels and
duration after AAV-MOCS1 transduction of both neonatal
and adolescent mice appear to be sufficient to maintain
an asymptomatic phenotype. Moreover, we showed that
a nonintegrating vector such as AAV16,17 has the potential
to rescue a young and rapidly growing organism. The ob-
served decrease over time of EGFP expression after trans-
duction of neonatal mice most likely reflects a dilution
effect caused by this growth. This dilution also appears to
be responsible for the higher mortality of the transduced
neonates (fig. 2a), as compared with the animals trans-
duced in adolescence (fig. 2b). Nonetheless, by the time
this article was prepared, the amount of vector genomes
delivered appeared to be sufficient to maintain transgene
expression in a relevant number of hepatocytes in three
of these animals for 15 mo. Furthermore, it can be ex-
pected that diffusable cPMP is produced in other trans-
duced tissues (fig. 3l–3u), thereby adding to the necessary
supply of detoxifying enzymes with their essential
cofactor.
We have reported elsewhere that Mocs1-deficient mice
supplemented with purified cPMP show bilateral kidney
obstruction at age 20 d, corresponding to high urinary
levels of xanthine.4 We have also confirmed that the ob-
structing deposits actually represent crystallized xanthine
(data not shown). Deceased or sacrificed animals of the
first AAV-MOCS1–treated series (neonatally transduced)
showed renal obstruction to various degrees. Mice ho-
mozygous for isolated xanthine oxidoreductase (XOR)
deficiency are runted and do not live beyond age 6 wk.18
These observations are in contrast to the course of hu-
man xanthinuria type 1 and 2, both of which are char-
acterized by XOR deficiency in combination with normal
sulphite oxidase activities. The majority of affected hu-
mans are asymptomatic, and renal stones develop only
occasionally.19,20
We believe that the different courses of human and mu-
rine XOR deficiency are due to the much lower pH of
murine urine,21 as compared with human urine, which
reduces the solubility of xanthine.22 This belief is corrob-
orated by the absence of xanthine stones or renal failure
in the described cases of human MoCo deficiency,23 in
which the clinical course is indistinguishable from that of
isolated sulphite oxidase deficiency.24
We therefore speculate that treatment of human MoCo
deficiency can focus on the treatment of sulphite oxidase
deficiency. The animals treated at age 40 d with AAV-
MOCS1 do not show any kidney abnormalities, which ex-
plains the almost-complete survival in this series. The
timely death of the offspring from these animals indicates
that the germline is not affected by this treatment.25
It remains to be seen whether the described therapy will
allow reversal of the neurological damage that is observed
in many patients, sometimes at birth. However, we have
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demonstrated that an early treatment can completely sup-
press the phenotype. A successful application in humans
should pave the way for prenatal screening procedures,
allowing accelerated intervention. Since the vectors used
in this study contain the human rather than the murine
MOCS1 sequence, these constructs could be used for clin-
ical studies without further modification.
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